middl
east
respiratori
syndrom
mer
emerg
infecti
diseas
first
identifi
june
caus
novel
merscoronaviru
merscov
merscov
zoonot
viru
bat
natur
reservoir
possibl
dromedari
camel
intermedi
host
merscov
infect
human
especi
elderli
peopl
diabet
chronic
lung
diseas
immunocompromis
person
caus
sever
diseas
high
mortal
mer
outbreak
result
laboratoryconfirm
case
includ
death
august
still
possibl
merscov
spread
within
healthcar
facil
number
case
link
mer
case
report
saudi
arabia
south
korea
second
largest
countri
travelassoci
mer
case
trace
back
saudi
arabia
continu
spread
merscov
possibl
cameltohuman
humantohuman
transmiss
rais
worldwid
concern
call
immedi
step
develop
effect
safe
vaccin
genom
merscov
encod
least
four
uniqu
accessori
protein
two
replicas
protein
open
read
frame
four
major
structur
protein
includ
spike
envelop
e
nucleocapsid
n
membran
protein
accessori
protein
play
nonessenti
role
merscov
replic
like
structur
protein
interferon
antagonist
modul
vivo
replic
effici
andor
pathogenesi
case
sarscov
protein
merscov
maintain
differ
function
viru
replic
e
protein
exampl
involv
virul
delet
ecod
gene
result
replicationcompet
propagationdefect
virus
attenu
virus
protein
particularli
essenti
mediat
viru
bind
cell
express
receptor
dipeptidyl
receptorbind
domain
rbd
subunit
wherea
subunit
subsequ
mediat
viru
entri
via
fusion
viru
target
cell
membran
therefor
viral
structur
protein
particularli
protein
may
serv
target
vaccin
develop
demonstr
circul
human
merscov
strain
repres
one
singl
serotyp
viru
isol
part
outbreak
differ
prototyp
strain
replic
interferon
escap
respons
serum
neutral
suggest
vaccin
develop
base
prototyp
viru
strain
unlik
affect
success
viru
strain
mer
vaccin
avail
human
use
vaccin
merscov
thu
far
develop
laboratori
categor
base
viral
vector
adenoviru
ad
modifi
vaccinia
viru
ankara
mva
base
recombin
viral
protein
dna
nanoparticl
recombin
viru
tabl
viral
vectorbas
mer
vaccin
use
fulllength
protein
merscov
code
antigen
exhibit
immunogen
vaccin
anim
report
indic
recombin
vector
encod
fulllength
extracellular
domain
merscov
protein
induc
merscov
sspecif
antibodi
respons
immun
mice
neutral
merscov
infect
vitro
vector
express
fulllength
protein
merscov
elicit
merscovspecif
antibodi
respons
neutral
antibodi
tcell
respons
immun
mice
moreov
viral
vector
mvabas
mer
vaccin
express
viral
protein
term
mvamerss
demonstr
efficaci
merscov
infect
mice
studi
suggest
potenti
appli
merscov
protein
vaccin
target
german
center
infect
research
dzif
support
phase
clinic
trial
mvamerss
vaccin
candid
human
usd
million
award
initi
trial
addit
viral
vectorbas
vaccin
vaccin
base
recombin
merscov
protein
particular
rbd
demonstr
efficaci
protect
immun
anim
merscov
infect
sever
fragment
includ
residu
rbd
merscov
shown
induc
merscov
neutral
antibodi
respons
mice
andor
rabbit
thu
similar
rbd
sever
acut
respiratori
syndrom
coronaviru
sarscov
merscov
rbd
also
contain
critic
neutral
domain
cnd
capabl
elicit
highli
potent
neutral
antibodi
protect
immun
infect
merscov
particularli
fragment
contain
residu
merscov
rbd
identifi
cnd
abl
protect
mice
merscov
notabl
effect
immunogen
protein
could
induc
potent
neutral
antibodi
respons
similar
rais
high
dose
respect
report
confirm
rbdcnd
merscov
protein
import
target
develop
mer
subunit
vaccin
dna
vaccin
proven
effect
merscov
infect
optim
dna
vaccin
encod
fulllength
protein
merscov
abl
elicit
antigenspecif
neutral
antibodi
mice
camel
rhesu
macaqu
nonhuman
primat
nhp
six
eight
vaccin
macaqu
show
radiograph
evid
infiltr
merscov
challeng
interestingli
potent
antigenspecif
cellular
immun
respons
induc
immun
macaqu
suggest
cell
respons
may
also
play
role
merscov
protect
inovio
pharmaceut
inc
collabor
geneon
life
scienc
perform
phase
clinic
trial
dnabas
vaccin
addit
dnaonli
strategi
dnaprim
proteinboost
could
altern
vaccin
approach
merscov
reveal
fulllength
dna
prime
subunit
protein
boost
immun
mice
nhp
induc
robust
neutral
antibodi
respons
sever
merscov
strain
protect
nhp
merscov
challeng
potenti
candid
suggest
mer
vaccin
exampl
purifi
merscov
fulllength
nanoparticl
combin
appropri
adjuv
could
elicit
neutral
antibodi
immun
mice
use
revers
genet
recombin
merscov
may
effici
replic
cell
cultur
human
cell
line
broad
tissu
tropism
allow
engin
mutant
merscov
lack
structur
e
protein
rescu
propag
cell
express
e
protein
tran
thu
provid
platform
develop
liveattenu
recombin
merscovbas
vaccin
induct
neutral
antibodi
key
prevent
merscov
infect
support
fact
reduct
lung
pathogenesi
protect
merscov
infect
correl
neutral
antibodi
level
anim
model
addit
vaccin
enjoy
high
safeti
profil
combin
abil
induc
broadspectrum
immun
respons
strong
protect
neutral
antibodi
top
prioriti
develop
efficaci
protect
immun
mer
candid
vaccin
necess
evalu
appropri
anim
model
thu
move
clinic
trial
nhp
rhesu
macaqu
common
marmoset
model
camel
model
establish
util
purpos
howev
use
nhp
camel
model
financi
facil
restrict
mani
research
fortun
recent
advanc
establish
small
anim
model
includ
mous
model
mous
model
provid
portabl
econom
platform
assess
efficaci
mer
candid
vaccin
despit
fact
anim
model
advantag
disadvantag
although
promis
recombin
merscovbas
vaccin
need
character
suitabl
merscov
anim
model
confirm
efficaci
safeti
viral
vectorbas
vaccin
hand
may
show
protect
immun
challeng
mous
anim
howev
vaccin
might
safeti
concern
presenc
preexist
immun
human
case
ad
potenti
induc
harm
immun
respons
thu
safeti
test
strongli
recommend
also
vaccin
type
might
lead
incomplet
protect
fail
protect
age
group
shown
case
sarscov
vaccin
comparison
recombin
proteinbas
subunit
vaccin
possess
highest
safeti
profil
util
fulllength
spike
protein
subunit
eg
fragment
eg
rbd
antigen
presenc
suitabl
adjuv
type
vaccin
gener
abl
induc
higher
titer
neutral
antibodi
respons
elicit
vaccin
type
easili
inject
via
differ
pathway
includ
intramuscular
inject
adopt
rout
human
vaccin
importantli
mer
subunit
vaccin
shown
protect
merscov
infect
challeng
mous
andor
nhp
model
demonstr
abil
scaleup
andor
human
clinic
trial
among
recombin
proteinbas
subunit
vaccin
believ
rbdbase
vaccin
effect
safer
base
fulllength
protein
rbd
contain
cnd
protein
highli
potent
neutral
antibodi
target
rbd
recombin
protein
contain
rbd
induc
strong
neutral
antibodi
respons
protect
vaccin
anim
merscov
infect
contrast
fulllength
protein
contain
nonneutr
immunodomin
domain
may
compromis
immunogen
cnd
rbd
even
induc
virusenhanc
harm
immun
respons
demonstr
protein
sarscov
may
one
reason
develop
fulllength
proteinbas
sar
vaccin
discontinu
one
may
critic
vaccin
base
rbd
sequenc
current
merscov
strain
might
effect
futur
emerg
merscov
strain
mutat
rbd
problem
rbdbase
vaccin
rbd
contain
sever
conform
neutral
epitop
thu
mutat
one
epitop
may
significantli
affect
neutral
activ
antibodi
elicit
epitop
exampl
rbdspecif
mab
could
neutral
strain
merscov
whose
rbd
contain
mutat
suscept
neutral
anoth
merscov
rbdspecif
mab
previou
studi
demonstr
rbd
sarscov
strain
contain
six
differ
conform
neutral
epitop
induc
antibodi
vaccin
anim
neutral
activ
sarscov
strain
test
includ
caus
earli
sar
outbreak
eg
strain
late
sar
pandem
eg
urbani
strain
well
sarslik
cov
strain
civet
sz
strain
although
epitop
outsid
merscov
rbd
may
neutral
activ
abil
significantli
lower
rbd
exampl
neutral
mab
target
epitop
merscov
respect
outsid
rbd
neutral
abil
potent
rbdspecif
mab
nevertheless
nonrbd
neutral
epitop
clearli
identifi
could
potenti
includ
vaccin
design
increas
breadth
strength
merscov
vaccin
common
knowledg
process
vaccin
approv
long
complic
regulatori
restrict
shortag
fund
case
point
mer
vaccin
urgent
need
yet
big
pharma
consist
refus
invest
fund
manufactur
develop
preclin
clinic
studi
base
uncertainti
immedi
return
invest
addit
adequ
financi
support
govern
entiti
guarante
gener
lack
fund
note
howev
firm
us
dzif
academi
germani
taken
first
step
toward
clinic
trial
two
mer
vaccin
base
dna
viral
vector
respect
big
pharma
govern
countri
part
world
take
note
signal
act
accordingli
